AR126159A1 - Ácido carboxílico que contiene compuestos de azetidinilo para el tratamiento de enfermedades neurodegenerativas - Google Patents
Ácido carboxílico que contiene compuestos de azetidinilo para el tratamiento de enfermedades neurodegenerativasInfo
- Publication number
- AR126159A1 AR126159A1 ARP220101582A ARP220101582A AR126159A1 AR 126159 A1 AR126159 A1 AR 126159A1 AR P220101582 A ARP220101582 A AR P220101582A AR P220101582 A ARP220101582 A AR P220101582A AR 126159 A1 AR126159 A1 AR 126159A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- alkyl
- halo
- groups
- compounds
- Prior art date
Links
- -1 AZETIDINYL COMPOUNDS Chemical class 0.000 title 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 abstract 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En el presente documento se proporcionan compuestos y composiciones de los mismos para modular S1P5. En algunas modalidades, los compuestos y composiciones se proporcionan para el tratamiento de enfermedades neurológicas. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: El anillo A es un resto de fórmula (2) o (3); Z¹ y Z² son independientemente CR⁰ o N; L es azetidinilo opcionalmente sustituido por 1 - 5 sustituyentes independientemente seleccionados de halo y alquilo C₁-C₆; cada R⁰ es independientemente H, -CN, alquilo C₁-C₆, cicloalquilo C₃-C₆, halo, haloalquilo C₁- C₆, o alcoxi C₁-C₆, o dos grupos R⁰ se toman junto con los átomos de carbono a los que se unen para formar un fenileno fusionado; R¹ es arilo C₆-C₁₀ o heteroarilo de 5- a 6-miembros, cada uno opcionalmente sustituido por 1 - 5 grupos R, en donde el heteroarilo contiene 1 - 3 heteroátomos seleccionados de nitrógeno y oxígeno; cada R es independientemente halo, alquilo C₁-C₆, haloalquilo C₁-C₆, alcoxi C₁-C₆, o cicloalquilo C₃-C₆, o dos grupos R se toman junto con los átomos de carbono a los que se unen para formar un fenileno fusionado; R² es H o alquilo C₁-C₆; R³ es -(CH₂)ˣ-CO₂H; o la línea discontinua entre R² y R³ representa una estructura de anillo donde R² y R³ son tomados junto con el átomo de nitrógeno al que se unen para formar un heterociclilo de 4- a 6-miembros sustituido por 1 - 5 grupos R⁴, en donde al menos un grupo R⁴ es -CO₂H; x es 1 - 5; cada R⁴ es independientemente -CO₂H, halo, alquilo C₁-C₆, haloalquilo C₁-C₆, o alcoxi C₁-C₆; R⁵ y R⁶ son independientemente H o alquilo C₁-C₆; y n es 0 o 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211313P | 2021-06-16 | 2021-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126159A1 true AR126159A1 (es) | 2023-09-27 |
Family
ID=82595041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101582A AR126159A1 (es) | 2021-06-16 | 2022-06-15 | Ácido carboxílico que contiene compuestos de azetidinilo para el tratamiento de enfermedades neurodegenerativas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11919879B2 (es) |
| EP (1) | EP4355729A1 (es) |
| JP (1) | JP2024522718A (es) |
| KR (1) | KR20240021883A (es) |
| CN (1) | CN117500785A (es) |
| AR (1) | AR126159A1 (es) |
| AU (1) | AU2022291768A1 (es) |
| BR (1) | BR112023023420A2 (es) |
| CA (1) | CA3217423A1 (es) |
| IL (1) | IL308122A (es) |
| MX (1) | MX2023014197A (es) |
| TW (1) | TW202317534A (es) |
| WO (1) | WO2022266162A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217423A1 (en) * | 2021-06-16 | 2022-12-22 | Jeffrey M. Schkeryantz | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| JP2026500504A (ja) * | 2022-12-16 | 2026-01-07 | セルジーン コーポレーション | Ｓ１ｐ５モジュレーターとしてのヘテロ環化合物 |
| CN121399098A (zh) | 2023-06-30 | 2026-01-23 | 赛诺菲 | 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法 |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO167087C (no) | 1985-10-25 | 1991-10-02 | Secr Defence Brit | Fremgangsmaate for fremstilling av en nitratester. |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| AU716493B2 (en) | 1995-09-01 | 2000-02-24 | Pharmacia & Upjohn Company | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings |
| WO2000005214A2 (en) | 1998-07-24 | 2000-02-03 | Pfizer Inc. | Isoquinolines as urokinase inhibitors |
| EP1429771B1 (en) | 2001-08-30 | 2009-08-12 | ChemoCentryx Inc | Bicyclic compounds as inhibitors of chemokine binding to us28 |
| AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| US7220734B2 (en) | 2002-12-20 | 2007-05-22 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EA017198B1 (ru) | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
| WO2008055959A1 (en) | 2006-11-09 | 2008-05-15 | Galapagos N.V. | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
| WO2010056788A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| MX2012013128A (es) | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| MA34300B1 (fr) | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CA2872989A1 (en) | 2012-05-09 | 2013-11-14 | Zoetis Llc | Azetidine derivatives as antiparasitic agents |
| AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
| EP2925741B1 (en) | 2012-11-16 | 2016-10-26 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
| EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| AU2015204210B2 (en) | 2014-01-06 | 2019-07-18 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| JP6483156B2 (ja) | 2014-05-07 | 2019-03-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ |
| US20170327457A1 (en) | 2014-09-09 | 2017-11-16 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
| WO2017019540A2 (en) | 2015-07-24 | 2017-02-02 | Yale University | Inhibitors of n-linked glycosylation and methods using same |
| MY196174A (en) | 2015-10-12 | 2023-03-20 | Chong Kun Dang Pharmaceutical Corp | Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the Same |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| ES2965264T3 (es) | 2016-03-09 | 2024-04-11 | Raze Therapeutics Inc | Inhibidores de la 3-fosfoglicerato deshidrogenasa y sus usos |
| US20200321533A1 (en) | 2016-05-24 | 2020-10-08 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018153849A1 (en) | 2017-02-21 | 2018-08-30 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| KR102700664B1 (ko) | 2017-08-07 | 2024-08-29 | 조인트 스탁 컴퍼니 “바이오케드” | Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물 |
| JP7281469B2 (ja) | 2018-01-19 | 2023-05-25 | イドーシア ファーマシューティカルズ リミテッド | Ｃ５ａ受容体調節剤 |
| US10695334B2 (en) | 2018-08-16 | 2020-06-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| KR102754524B1 (ko) | 2018-08-17 | 2025-01-13 | 제넨테크, 인크. | 유방암 치료를 위한 진단 및 치료 방법들 |
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CA3143280A1 (en) | 2019-07-03 | 2021-01-07 | F. Hoffmann-La Roche Ag | Heterocyclic monoacylglycerol lipase (magl) inhibitors |
| MX2022001820A (es) * | 2019-08-20 | 2022-03-17 | Ono Pharmaceutical Co | Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). |
| CN111704613B (zh) | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| KR20230124992A (ko) | 2020-12-23 | 2023-08-28 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 함유 인다닐화합물 |
| CA3217423A1 (en) * | 2021-06-16 | 2022-12-22 | Jeffrey M. Schkeryantz | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
-
2022
- 2022-06-15 CA CA3217423A patent/CA3217423A1/en active Pending
- 2022-06-15 AR ARP220101582A patent/AR126159A1/es unknown
- 2022-06-15 US US17/840,876 patent/US11919879B2/en active Active
- 2022-06-15 AU AU2022291768A patent/AU2022291768A1/en active Pending
- 2022-06-15 CN CN202280042673.6A patent/CN117500785A/zh active Pending
- 2022-06-15 IL IL308122A patent/IL308122A/en unknown
- 2022-06-15 KR KR1020247001145A patent/KR20240021883A/ko active Pending
- 2022-06-15 JP JP2023577349A patent/JP2024522718A/ja active Pending
- 2022-06-15 MX MX2023014197A patent/MX2023014197A/es unknown
- 2022-06-15 BR BR112023023420A patent/BR112023023420A2/pt not_active Application Discontinuation
- 2022-06-15 EP EP22743647.4A patent/EP4355729A1/en active Pending
- 2022-06-15 TW TW111122266A patent/TW202317534A/zh unknown
- 2022-06-15 WO PCT/US2022/033523 patent/WO2022266162A1/en not_active Ceased
-
2024
- 2024-01-25 US US18/422,500 patent/US20240270714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014197A (es) | 2024-01-18 |
| JP2024522718A (ja) | 2024-06-21 |
| EP4355729A1 (en) | 2024-04-24 |
| CA3217423A1 (en) | 2022-12-22 |
| KR20240021883A (ko) | 2024-02-19 |
| BR112023023420A2 (pt) | 2024-01-30 |
| TW202317534A (zh) | 2023-05-01 |
| WO2022266162A1 (en) | 2022-12-22 |
| US11919879B2 (en) | 2024-03-05 |
| IL308122A (en) | 2023-12-01 |
| US20240270714A1 (en) | 2024-08-15 |
| AU2022291768A1 (en) | 2023-11-30 |
| CN117500785A (zh) | 2024-02-02 |
| US20230028747A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126159A1 (es) | Ácido carboxílico que contiene compuestos de azetidinilo para el tratamiento de enfermedades neurodegenerativas | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| AR104533A1 (es) | Derivados de ácido ciclopropano carboxílico y sus usos como inhibidores de leucotrieno c₄ sintasa | |
| PE20251689A1 (es) | Moduladores de il-17a basados en diciclopropilo y usos de estos | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| AR124008A1 (es) | 1,4-diazepanonas bicíclicas y sus usos terapéuticos | |
| AR128432A1 (es) | Tetrahidropiridopirimidinas y análogos relacionados para la inhibición de yap / taz-tead | |
| AR127483A1 (es) | Compuestos antibacterianos | |
| AR119341A1 (es) | Profármacos de moduladores del receptor de nmda | |
| AR123582A1 (es) | Triazinonas inhibidores de la producción de inflamasoma de nlrp3 | |
| AR127139A1 (es) | Inhibidores de lpxc y usos de estos | |
| AR127255A1 (es) | NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM | |
| AR123700A1 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR123701A1 (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR123884A1 (es) | Compuestos moduladores del cftr, composiciones y usos de estos | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| AR125363A1 (es) | Nuevos derivados de pirazolo[1,5-a]pirimidina como ligandos sigma | |
| AR129053A1 (es) | Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos | |
| AR125750A1 (es) | Compuestos herbicidas | |
| CL2022002106A1 (es) | Moduladores de nampt. | |
| AR128672A1 (es) | Compuestos y métodos para el tratamiento de infecciones virales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |